Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Mar;11(1):61-5.
doi: 10.4103/2008-322X.180700.

Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy

Cihan Ünlü  1 , Gurkan Erdogan  1 , Tugba Aydogan  1 , Betul Ilkay Sezgin Akcay  1 , Esra Kardes  1 , Gulunay Akcali Kiray  1 , Tahir Kansu Bozkurt  1
Affiliations

Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy

Cihan Ünlü et al. J Ophthalmic Vis Res. 2016 Jan-Mar.

Abstract

Purpose: To compare the outcomes of treatment with intravitreal bevacizumab (IVB) versus observation in central serous chorioretinopathy (CSCR).

Methods: In a retrospective comparative study, records of 45 patients with CSCR were reviewed. Twenty-two patients received IVB (1.25 mg/0.05 ml) while 23 subjects were observed. All subjects underwent measurement of best corrected visual acuity (BCVA) and intraocular pressure (IOP), dilated fundus examination and optical coherence tomography (OCT) imaging at baseline and follow up visits. Outcome measures included central macular thickness (CMT) and BCVA in logarithm of minimum angle of resolution (logMAR) notations.

Results: Mean age was 44.1 ± 9.3 (range: 24 to 64) years and mean follow-up period was 10.4 ± 11.2 (range: 3 to 43; median: 6) months. All patients demonstrated resolution of neurosensory detachment and improvement in visual acuity. At final visit, there was no significant difference in mean CMT between the IVB and observation groups (275 vs 284 μm, P> 0.05). Mean baseline logMAR visual acuity was 0.38 ± 0.24 in the IVB group which improved to 0.24 ± 0.31 at final follow-up (P = 0.011); mean baseline logMAR visual acuity was 0.42 ± 0.28 in the observation group and improved to 0.12 ± 0.18 (P = 0.001). Visual improvement was more marked in the observation group (0.30 vs 0.14 logMAR, P< 0.05) and mean final visual acuity was also significantly better (P = 0.05).

Conclusion: There was no significant difference between IVB injection and observation in terms of anatomical outcomes of treatment for CSCR. In terms of visual outcomes, observation was superior to IVB injection.

Keywords: Central Serous Chorioretinopathy; Intravitreal Bevacizumab (Avastin); Macular Thickness; Observation.

PubMed Disclaimer

References

    1. Gass JD. Pathogenesis of disciform detachment of neuroepithelium: II. Idiopathic central serous choriodopathy. Am J Ophthalmol. 1967;63:587–615. - PubMed
    1. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96:854–859. - PubMed
    1. Loo RH, Scott IU, Flynn HW, Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. - PubMed
    1. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9:37–41. - PubMed
    1. Prünte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int Ophthalmol. 1995;19:77–82. - PubMed